Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
June 28, 2023 02:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
June 23, 2023 02:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 23, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
June 22, 2023 02:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
June 16, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 16, 2023 – 7.00 PM CET Oxurion NV...
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC
June 15, 2023 13:02 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
June 15, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
June 12, 2023 14:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 12, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care...
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
June 12, 2023 02:00 ET
|
Oxurion NV
Top-line Data Expected in Q4 2023 Leuven, BELGIUM, Boston, MA, US – June 12, 2023 – 8:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
June 09, 2023 02:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
June 06, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...